-
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient delivery option designed to provide cash-paying patients with all dose strengths of Wegovy at a reduced cost of USD 499 per month. Program DetailsThe introduction of NovoCare Pharmacy mirrors the approach taken by US major…
-
Antengene’s Xpovio Receives Marketing Approval in Indonesia
•
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced receiving marketing approval in Indonesia for its Xpovio (selinexor). The approval grants the drug three indications in the Southeast Asian country. Indications ApprovedThe drug is approved for: Drug BackgroundXpovio, the world’s first and only FDA-approved oral XPO1 inhibitor, was discovered by US-based…
-
Sino Medical Sciences’ HT Supreme Stent System Gains Vietnamese Marketing Approval
•
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) announced that it has received marketing approval from the Ministry of Health of Vietnam for its HT Supreme drug-eluting stent system. The approval allows the product to be used to improve the diameter of the coronary artery lumen in symptomatic heart disease…
-
Yifan Pharma Secures Rights to Bayer’s Stivarga and Nexavar in China
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN), securing exclusive rights to promote the German company’s Stivarga (regorafenib) and Nexavar (sorafenib) in mainland China. Yifan Pharma’s PortfolioYifan Pharma has a team of 300 specialists in oncology marketing and sales. Its product lineup includes…
-
Major Policy Directions in China’s Healthcare Arena: A Comprehensive Breakdown
•
In a momentous address at the Third Session of the 14th National People’s Congress on March 5, Chinese Premier Li Qiang presented the Government Work Report, offering profound insights into the country’s healthcare policy direction. This report not only underscores the government’s commitment to public welfare but also charts a…
-
RongCan Biotech’s mRNA HPV Vaccine Receives FDA Clinical Approval
•
China-based mRNA specialist RongCan (Shanghai) Biotech Co., Ltd announced that it has received clinical approval from the US Food and Drug Administration (FDA) for its mRNA-based human papillomavirus (HPV) therapeutic vaccine. Clinical Approval and SignificanceThis approval marks a significant step forward in the development of therapeutic options for HPV-related conditions.…
-
Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies
•
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm Tenacia, a central nervous system (CNS) specialist incubated by Bain Capital. The collaboration aims to integrate Insilico’s cutting-edge generative AI drug discovery platform Pharma AI with Tenacia’s proprietary data assets to develop small molecule inhibitors…
-
Lexenpharm and Sun-Novo Partner on Long-Acting Asthma and COPD Drugs
•
China-based Lexenpharm has formed a partnership with compatriot firm Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) to develop LXP2311 and LXP0531, long-acting drugs targeting asthma and chronic obstructive pulmonary disease (COPD) for the mainland Chinese market. Partnership FocusThe collaboration leverages Lexenpharm’s technical capabilities in respiratory diseases and Sun-Novo’s clinical…
-
Baheal Pharmaceutical Gains Exclusive Rights to Roche’s MabThera in China
•
China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) last month reached an accord with Roche (SWX: ROG, OTCMKTS: RHHBY), securing exclusive market promotion rights to the Swiss giant’s MabThera (rituximab) in mainland China. Drug ProfileMabThera, the world’s first anti-CD20 monoclonal antibody (mAb), is used to treat Hodgkin…
-
Zhejiang Huahai’s HB0034 Meets Primary Endpoint in GPP Study
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its multi-center, double-blinded, randomized, placebo-parallel controlled pivotal study for HB0034, a Category 1 biologic product for acute generalized pustular psoriasis (GPP), has achieved the primary efficacy endpoint and all secondary efficacy endpoints. Study ResultsGPP is a rare, life-threatening, systemic neutropenic…
-
CStone Pharmaceuticals and SteinCares Ink Licensing Deal for PD-L1 Inhibitor in Latin America
•
China-based CStone Pharmaceuticals (HKG: 2616) and Costa Rica-based drug maker and distributor SteinCares have entered into a licensing agreement. Under the terms of the agreement, SteinCares will obtain exclusive commercialization rights to CStone’s anti-programmed death-ligand 1 (PD-L1) inhibitor sugemalimab (trade name: Cejemly) in the Latin American market, including Brazil, Argentina,…
-
Fosun Pharma’s 24-Valent Pneumococcal Vaccine Receives NMPA Approval for Phase I Trial
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) subsidiary Fosun Adgenvax (Chengdu) Biopharmaceutical Co.,Ltd. is set to commence a Phase I clinical study for its 24-valent pneumococcal polysaccharide conjugate vaccine in China, following clearance from the National Medical Products Administration (NMPA). Vaccine ProfileThe preventative biologic product is…
-
Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206
•
China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting the Turkiye-based firm exclusive distribution and marketing rights to its BAT2206, a biosimilar version of Roche’s Stelara (Ustekinumab). Partnership DetailsUnder the agreement, World Medicine will handle the import, regulatory filing, and sales of the drug…
-
Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents
•
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US partner Slate Run Pharmaceuticals and Premier, Inc. (NASDAQ: PINC), a healthcare-focused group purchasing organization (GPO) in the US. The collaboration centers on contrast agents. Partnership DetailsUnder the agreement, Premier’s members have the freedom to purchase…
-
Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies
•
US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement with Denmark-based Novo Nordisk A/S (NYSE: NVO). The collaboration, combining Novo’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology, is designed to discover tissue-targeting ligands and develop new therapeutic candidates…
-
MSD China Reorganizes to Boost Mature Product Lines
•
Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and President of MSD China, announced this week a significant adjustment to the company’s organizational structure. A new entrepreneur business unit will be established, focusing on the US giant’s mature products in the fields of infection,…
-
Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE
•
China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND) filing for its freeze-dried respiratory syncytial virus (RSV) mRNA vaccine has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). RSV and Vaccine TechnologyRSV is a common viral…
-
CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D
•
China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its Support Anti-tumor drugs R&D for Kids (SPARK) project within one month. This initiative marks a significant step forward in promoting the development of pediatric antitumor drugs. Project BackgroundThe SPARK project is a pilot effort in…
-
BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment
•
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change its name to BeOne Medicines Ltd, announced that it has received another indication approval from the US Food and Drug Administration (FDA) for its Tevimbra (tislelizumab). The PD – 1 inhibitor is now approved for…
-
Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars
•
Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year (YOY) increase in revenues, excluding foreign exchange effects, to USD 6.4 billion. Global PerformanceGlobally, Women’s Health revenues rose 5% YOY to USD 1.78 billion, primarily driven by a 17% growth in Nexplanon (etonogestrel implant) sales,…
